Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991029 · ClinicalTrials.gov registry record · Phase 3
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A Phase 3 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4,881
- Enrollment target
NCT00991029 is a Phase 3 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 4,881 participants.
The verdict
NCT00991029, a Phase 3 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4,881 participants
- Enrollment target
Study Summary
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale \[NIHSS\] score less than or equal to 3). TIAs are common \[25\], and are often harbingers of disabling strokes. Approximately 250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8 years \[32\], there are approximately 2.4 million TIA survivors. In a national survey, one in fifteen of those over 65 years old reported a history of TIA \[33\], which is equivalent to a prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed transient neurological events, the true incidence of TIA may be twice as high as the rates of diagnosis \[33\]. Based on our review of the National Inpatient Sample for 1997-2003, there were an average of 200,000 hospital admissions for TIA each year, with annual charges climbing quickly in the period to $2.6 billion in 2003. Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.
Interventions
- DRUG placebo
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,881 participants |
| Start Date | 2010-05-28 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00991029
The ClinicalTrials.gov registry entry for NCT00991029 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4,881 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00991029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00991029 about?
NCT00991029 is a clinical study titled "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial". A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an N...
What is the current status of trial NCT00991029?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4,881 participants. The study started on 2010-05-28. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT00991029?
The interventions under investigation include: placebo (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00991029?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.